Why First-Line Matters: Survival, Sequencing, and Support in EGFR-Mutated Lung Cancer
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Why First-Line Matters: Survival, Sequencing, and Support in EGFR-Mutated Lung Cancer
-
Lu par :
-
De :
À propos de ce contenu audio
Join Dr. Edgardo Santos and Dr. Luis Raez for a practical discussion on first-line decision-making in EGFR-mutated lung cancer and how early treatment choices shape survival, sequencing, and patient experience.
This episode explores why first-line therapy represents a critical window for long-term benefit, including the reality that many patients never reach later lines of treatment and the importance of early disease control. The speakers review guideline-supported first-line strategies, discuss how clinicians interpret survival and durability data, and examine the role of CNS disease as a key factor in treatment selection.
The conversation also addresses real-world implementation considerations, including adverse event management, administration and dosing factors, and how early patient education can improve treatment adherence and experience. Learn how interdisciplinary care teams provide proactive support to help optimize outcomes in the first months of therapy.
Tune in for key insights on optimizing first-line strategy and supporting patients from the start of therapy.